107 related articles for article (PubMed ID: 25402488)
1. A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.
Grudzinski JJ; Titz B; Kozak K; Clarke W; Allen E; Trembath L; Stabin M; Marshall J; Cho SY; Wong TZ; Mortimer J; Weichert JP
PLoS One; 2014; 9(11):e111652. PubMed ID: 25402488
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.
Lubner SJ; Mullvain J; Perlman S; Pishvaian M; Mortimer J; Oliver K; Heideman J; Hall L; Weichert J; Liu G
Cancer Invest; 2015; 33(10):483-9. PubMed ID: 26536061
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Pharmacokinetics and Dosimetry Studies of
Marsh IR; Grudzinski J; Baiu DC; Besemer A; Hernandez R; Jeffery JJ; Weichert JP; Otto M; Bednarz BP
J Nucl Med; 2019 Oct; 60(10):1414-1420. PubMed ID: 30926646
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.
Baiu DC; Marsh IR; Boruch AE; Shahi A; Bhattacharya S; Jeffery JJ; Zhao Q; Hall LT; Weichert JP; Bednarz BP; Otto M
J Nucl Med; 2018 Feb; 59(2):244-250. PubMed ID: 28747518
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems.
Morris ZS; Weichert JP; Saker J; Armstrong EA; Besemer A; Bednarz B; Kimple RJ; Harari PM
Radiother Oncol; 2015 Sep; 116(3):504-9. PubMed ID: 26123834
[TBL] [Abstract][Full Text] [Related]
6. Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404.
Besemer AE; Titz B; Grudzinski JJ; Weichert JP; Kuo JS; Robins HI; Hall LT; Bednarz BP
Phys Med Biol; 2017 Jul; 62(15):6008-6025. PubMed ID: 28682793
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.
Besemer AE; Grudzinski JJ; Weichert JP; Hall LT; Bednarz BP
Cancer Biother Radiopharm; 2019 Feb; 34(1):13-23. PubMed ID: 30351218
[TBL] [Abstract][Full Text] [Related]
8. [
Hall LT; Titz B; Baidya N; van der Kolk AG; Robins HI; Otto M; Perlman SB; Weichert JP; Kuo JS
Mol Imaging Biol; 2020 Apr; 22(2):434-443. PubMed ID: 31183841
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography.
Sathekge M; Wagener J; Smith SV; Soni N; Marjanovic-Painter B; Zinn C; Van de Wiele C; D'Asseler Y; Perkins G; Zeevaart JR
Nuklearmedizin; 2013 Dec; 52(6):222-7. PubMed ID: 24108524
[TBL] [Abstract][Full Text] [Related]
10. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
11. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
12. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.
Maddahi J; Czernin J; Lazewatsky J; Huang SC; Dahlbom M; Schelbert H; Sparks R; Ehlgen A; Crane P; Zhu Q; Devine M; Phelps M
J Nucl Med; 2011 Sep; 52(9):1490-8. PubMed ID: 21849402
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
Lam K; Chan C; Done SJ; Levine MN; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
16. (S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry.
Smolarz K; Krause BJ; Graner FP; Wagner FM; Hultsch C; Bacher-Stier C; Sparks RB; Ramsay S; Fels LM; Dinkelborg LM; Schwaiger M
J Nucl Med; 2013 Jun; 54(6):861-6. PubMed ID: 23568366
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid ether analogs for the detection of colorectal tumors.
Deming DA; Maher ME; Leystra AA; Grudzinski JP; Clipson L; Albrecht DM; Washington MK; Matkowskyj KA; Hall LT; Lubner SJ; Weichert JP; Halberg RB
PLoS One; 2014; 9(10):e109668. PubMed ID: 25286226
[TBL] [Abstract][Full Text] [Related]
18. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
19. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
20. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT.
Beauregard JM; Croteau E; Ahmed N; van Lier JE; Bénard F
J Nucl Med; 2009 Jan; 50(1):100-7. PubMed ID: 19091905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
